Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Substudy


March 21, 2018—Edwards Lifesciences Corporation announced that enrollment is complete in the CT imaging substudy within the PARTNER 3 trial of Edwards' Sapien 3 valve. The randomized substudy is examining leaflet mobility of both the Sapien 3 valve and surgical heart valves in low-risk patients undergoing valve replacement for the treatment of severe aortic stenosis.

According to the company, enrollment was already complete for the PARTNER 3 main study of the Sapien 3 valve in low-risk patients. Edwards previously stated that it continues to anticipate that data from the PARTNER 3 trial will be presented at ACC 2019, the American College of Cardiology's 68th annual scientific session to be held March 16–18 in New Orleans, Louisiana. The company expects to receive US Food and Drug Administration approval for the indication in late 2019.

In addition, Edwards is studying the Sapien 3 Ultra system as part of a single-arm multicenter trial of up to 30 intermediate-risk patients that will support the European regulatory filing for the Sapien 3 Ultra system.

The company advised that it now expects that the European launch of the Sapien 3 Ultra system will occur later in 2018 and it continues to expect the introduction of this system in the United States in late 2018.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.